Cytosorbents Corp. CTSO
Analyst Ratings
- Consensus
- Moderate Buy — 1 Buy · 1 Hold · 0 Sell (2 analysts)
- Avg. Price Target
- $5.38 (+30.8% upside)
Key Stats
- Today's Range
- $3.01 – $4.60
- 50-Day Range
- $2.84 – $9.43
- 52-Week Range
- $2.84 – $20.40
- Volume
- 685K shs
- Average Volume
- 35K shs
- Market Cap
- $9.64 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 43.13%
- Days to Cover
- 12.82
About Cytosorbents Corp.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Related Stocks
Compare head-to-head: CTSO vs SYK·CTSO vs BSX·CTSO vs RMD·CTSO vs BAX
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.